Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vedaclidine SCHEMBL995360 | 1.00 | CHRM1 (0.63) | CHRM1 | |
| SCHEMBL7821561 | 0.96 | CHRM1 (0.64) | CHRM1 | |
| SCHEMBL7810878 | 0.95 | CHRM1 (0.65) | CHRM1 | |
| SCHEMBL7818351 | 0.95 | CHRM1 (0.65) | CHRM1 | |
| SCHEMBL9559611 | 0.95 | CHRM1 (0.65) | CHRM1 | |
| SCHEMBL7819046 | 0.94 | CHRM1 (0.59) | CHRM1 | |
| Vedaclidine SCHEMBL7811668 | 0.93 | CHRM1 (0.56) | CHRM1 | |
| Vedaclidine SCHEMBL9058734 | 0.93 | CHRM1 (0.56) | CHRM1 | |
| SCHEMBL9090599 | 0.93 | CHRM1 (0.56) | CHRM1 | |
| SCHEMBL7811511 | 0.92 | CHRM1 (0.62) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186415-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2025-06-12 | — | — | US | claimed |
| EP-4489858-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | Harrow IP, LLC (US) | 2025-01-15 | — | — | EP | claimed |
| WO-2023172240-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | HARROW IP, LLC (US) | 2023-09-14 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8758816-B2 | Compositions comprising azelastine and methods of use thereof | MEDA PHARMACEUTICALS INC. (US) | 2014-06-24 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20100152147-A1 | Compositions Comprising Azelastine and Methods of Use Thereof | MEDA PHARMACEUTICALS INC. | 2010-06-17 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| EP-0735869-A1 | A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS | NOVO NORDISK A/S (DK) | 1996-10-09 | — | — | EP | claimed |
| WO-1996025154-A1 | TRANSDERMAL FORMULATION | ELI LILLY AND COMPANY (US) | 1996-08-22 | — | — | WO | claimed |
| EP-0727208-A1 | Transdermal formulation of a compound having muscarinic activity | ELI LILLY AND COMPANY (US) | 1996-08-21 | — | — | EP | claimed |
| WO-1996014316-A1 | A METHOD OF TREATING URINARY BLADDER DYSFUNCTIONS | NOVO NORDISK A/S (DK) | 1996-05-17 | — | — | WO | claimed |
| WO-1996013168-A1 | METHOD FOR TREATING ANXIETY | ELI LILLY AND COMPANY (US) | 1996-05-09 | — | — | WO | claimed |
| EP-0709095-A2 | Method for treating anxiety using a tetrahydropyridine or azabicyclic oxadiazole or thiadiazole compound | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | claimed |
| US-5488056-A | 1,2,5-THIADIAZOLE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-01-30 | — | — | US | claimed |
| WO-1995017180-A1 | A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS | NOVO NORDISK A/S (DK) | 1995-06-29 | — | — | WO | claimed |
| EP-0544779-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1993-06-09 | — | — | EP | claimed |
| WO-1992003433-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1992-03-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152147-A1 | Compositions Comprising Azelastine and Methods of Use Thereof | TAS2R5, HRH2, IL5 | CHRM1 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.